SAN Sanofi

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

PARIS, France – March 4, 2021 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company’s website: .

In addition, the Form 20-F is available on the website of the SEC () and the “Document d’Enregistrement Universel” is available on the website of the AMF (). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

 



About Sanofi



 



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.



 



With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



 



Sanofi, Empowering Life



 





Media Relations Contact

Ashleigh Koss

Tel: +1 (908) 981-8745





 



Sandrine Guendoul

Tel.: +33 (0)1 53 77 46 46









 
 



Investor Relations Contacts Paris

Eva Schaefer-Jansen

Arnaud Delepine

Yvonne Naughton



 



Investor Relations Contacts North America

Felix Lauscher

Fara Berkowitz

Suzanne Greco



 



IR main line:

Tel.: +33 (0)1 53 77 45 45





 







 



Attachment



EN
04/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release:  Sanofi’s Board of Directors proposes the appointment o...

Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director  Paris, March 5, 2026. The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting of shareholders scheduled for April 29, 2026, the appointment of Christel Heydemann as an independent director, as well as the renewal of the mandates of Christophe Babule and Jean-Paul Kress.  Patrick Kron, independent director and Chairman of the Nomination,...

 PRESS RELEASE

Communiqué de presse : Le Conseil d’administration de Sanofi propose l...

Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante   Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante  Paris, le 5 mars 2026. Le Conseil d’administration de Sanofi a décidé de proposer, dans le cadre de la prochaine Assemblée générale des actionnaires prévue le 29 avril 2026, la nomination de Christel Heydemann en qualité d’administratrice indépendante et le renouvellement des mandats de Christophe Babule et Jean-P...

 PRESS RELEASE

Press Release: Filing of an amendment to the French “Document d’Enregi...

Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). This amendment notably includes additions to the report on corporate governance established in accordance with French law. ...

 PRESS RELEASE

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrem...

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris, le 4 mars 2026. Sanofi annonce avoir déposé ce jour un amendement à son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France. Cet amendement intègre notamment des compléments au (i) rapport de gestion et au (ii) rapport sur le gouvernement d’entreprise. Le document pe...

 PRESS RELEASE

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignati...

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 La désignation s’appuie sur les données positives d’une étude de phase 2 sur le rilzabrutinib dans la maladie liée aux IgG4Il s’agit de la troisième désignation mondiale de médicament orphelin pour le rilzabrutinib dans le traitement de la maladie liée aux IgG4, soulignant l’engagement de Sanofi dans la lutte contre les maladies rares à médiation...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch